Overview

A Phase II Evaluation of Dasatinib (Sprycel®, NSC #732517) in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma

Status:
Completed

Trial end date:
1969-12-31

Target enrollment:

Participant gender:

Summary

Dasatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. This phase II trial is studying how well dasatinib works in treating patients with persistent or recurrent ovarian epithelial cancer, fallopian tube cancer, or primary peritoneal cancer.

Phase:

Phase 2

Details

Lead Sponsor:

Gynecologic Oncology Group

Collaborator:

National Cancer Institute (NCI)

Treatments:

Dasatinib